Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities

被引:0
作者
Carrie Lenneman
David Harrison
S. Lindsey Davis
Lavanya Kondapalli
机构
[1] University of Alabama at Birmingham,Division of Cardiology, Department of Medicine
[2] University of Colorado,Division of Cardiology, Department of Medicine
[3] University of Colorado,Division of Medical Oncology, Department of Medicine
来源
Current Treatment Options in Oncology | 2022年 / 23卷
关键词
Carcinoid heart disease; Carcinoid syndrome; Neuroendocrine tumor; Tricuspid valve disease; Pulmonic valve disease; Valvular heart disease; Somatostatin analogs; Cardiac surgery; Carcinoid crisis;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiac surgery with tricuspid valve and potentially pulmonic valve replacement at an experienced center is currently the most effective strategy available for the treatment of carcinoid heart disease. Cardiac surgery for carcinoid heart disease requires a multidisciplinary team including cardiology, medical oncology, cardiothoracic anesthesia, and cardiac surgery. Without cardiac surgery, morbidity and mortality from carcinoid heart disease is high. Aggressive management of carcinoid before and after cardiac surgery is critical. Over time, though, circulating carcinoid hormones can lead to destruction of prosthetic valves as well, resulting in recurrent right heart failure. Percutaneous options for valve repair may be on the horizon for management of carcinoid heart disease.
引用
收藏
页码:1793 / 1803
页数:10
相关论文
共 143 条
[1]  
Modlin IM(1997)An analysis of 8305 cases of carcinoid tumors Cancer. 79 813-829
[2]  
Sandor A(1993)Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients Circulation. 87 1188-1196
[3]  
Pellikka PA(2021)Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management Cardiology. 146 65-73
[4]  
Tajik AJ(2009)Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor J Clin Oncol. 27 4293-4299
[5]  
Khandheria BK(2013)Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study Int J Cardiol. 168 5167-5173
[6]  
Seward JB(2021)Managing carcinoid heart disease in patients with neuroendocrine tumors Ann Endocrinol (Paris). 82 187-192
[7]  
Callahan JA(2020)Carcinoid Syndrome: A Review Cureus. 12 4656-4663
[8]  
Pitot HC(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol. 27 1556-1557
[9]  
Kvols LK(2014)Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med. 371 125-135
[10]  
Jin C(2017)Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors N Engl J Med. 376 440-451